Dystrophic Epidermolysis Bullosa Treatment Market Size to Hit US$ 715 Million by 2030

As per Vision research Reports, the global dystrophic epidermolysis bullosa treatment market size is predicted to hit around US$ 715 million by 2030 from valued US$ 415 Mn in 2020, expanding growth at a CAGR of 5.1% from 2022 to 2030.

Dystrophic epidermolysis bullosa (DEB) is the second most common form of epidermolysis bullosa. The prevalence of DEB varies from 1 per 49,000 inhabitants in Scotland to 1 per 420,168 in the U.S. According to the U.S. National Library of Medicine, the prevalence of recessive and dominant dystrophic epidermolysis bullosa is estimated at 3.3 per million people.

Immediate Delivery Available | Get the sample copy of report@ https://www.visionresearchreports.com/report/sample/38187

Rise in prevalence of dystrophic epidermolysis bullosa and surge in research for managing dystrophic epidermolysis bullosa are projected to drive the global dystrophic epidermolysis bullosa treatment market during the forecast period.

Advent of New Treatment Modalities to Drive Global Market

The increasing prevalence of epidermolysis bullosa– a set of hereditary skin blistering diseases has prompted researchers and scientists to seek newer treatment modalities – a factor that is expected to drive the global dystrophic epidermolysis bullosa treatment market during the assessment period. Furthermore, as researchers have gained immense knowledge pertaining to the genetic mutation of dystrophic epidermolysis bullosa, newer treatment modalities are currently making inroads into the global dystrophic epidermolysis bullosa treatment market. The increasing understanding of disease etio-pathogenesis is a top factor that is accelerating the development of new and cutting-edge therapy alternatives. In the current scenario, cell-based and first gene therapies are increasingly being tested in clinical trials and at the preclinical level. Moreover, the increasing knowledge of various secondary disease mechanisms has paved the way for clinical testing and development of symptom-relief therapies, including dystrophic epidermolysis bullosa treatment– a major factor that is anticipated to fuel the growth of the global dystrophic epidermolysis bullosa treatment market during the assessment period.

Scope of The Report

Research and Development Activities in Full Swing amid COVID-19 Pandemic

The COVID-19 pandemic is expected to have a moderate impact on the overall growth of the global dystrophic epidermolysis bullosa treatment market during the assessment period. Research and development activities for dystrophic epidermolysis bullosa treatment are underway to identify the potential threat of the novel SARS-CoV-2 virus to patients suffering from dystrophic epidermolysis bullosa. Several studies have revealed that patients suffering from epidermolysis bullosa, particularly with syndromic forms are at a higher risk of acquiring the novel COVID-19 infection.

Overall, the outbreak of the COVID-19 pandemic is expected to accelerate research and development activities, thereby opening new avenues.

Immediate Delivery Available | Buy this Premium Research Report@ https://www.visionresearchreports.com/report/cart/38187

Strides Taken by Gene Therapy and Tissue Engineering to Fuel Adoption

Due to the notable progress made by gene therapy and tissue engineering, dystrophic epidermolysis bullosa treatment has improved by a considerable margin. Moreover, apart from these alternatives, stem cell transplantation and gene correction are some of the other treatment alternatives that are likely to gain adoption in the global dystrophic epidermolysis bullosa treatment market during the assessment period. A number of research and development activities has indicated that in vitro gene therapy of keratinocyte stem cells and transplanting the same into the skin is one of the most promising and novel treatments that is likely to gain considerable adoption in the upcoming years. Scientists and stakeholders operating in the current dystrophic epidermolysis bullosa treatment market landscape are also focusing on enhancing the clinical features in epidermolysis bullosa patients by relying on in vitro gene therapy of stem cell keratinocytes– a factor that is projected to boost the global dystrophic epidermolysis bullosa treatment market during the assessment period.

Report Highlights

In terms of treatment type, the global dystrophic epidermolysis bullosa treatment market has been classified into antibiotics, corticosteroids, opioid analgesics, anticonvulsant, and others. The antibiotics segment dominated the global dystrophic epidermolysis bullosa treatment market in 2019 and the trend is projected to continue during the forecast period. A large number of antibiotics is in late phases of clinical pipeline trials and are likely to be commercialized between 2019 and 2025. Anticipated launch and adoption of antibiotics to address unmet medical needs in dystrophic epidermolysis bullosa treatment are expected to propel the segment during the forecast period.

Based on service provider, the global dystrophic epidermolysis bullosa treatment market has been bifurcated into dominant dystrophic epidermolysis bullosa (DDEB) and recessive dystrophic epidermolysis bullosa (RDEB). The dominant dystrophic epidermolysis bullosa (DDEB) segment dominated the global dystrophic epidermolysis bullosa treatment market due to large number of patients suffering from dominant dystrophic epidermolysis bullosa. According to the National EB Registry, the overall prevalence of EB is 11.07 per one million live births. The prevalence of DDEB and RDEB is 1.49 and 1.35 per one million live births, respectively.

North America dominated the global dystrophic epidermolysis bullosa treatment market in 2020 and the trend is anticipated to continue during the forecast period. The rise in population suffering from various diseases in North America has increased the number of patients visiting hospitals. Hence, the consumption of dystrophic epidermolysis bullosa treatment products is expected to increase during the forecast period. North America’s large share of the global dystrophic epidermolysis bullosa treatment market can be attributed to high cost of biologic drugs compared to other regions. It is a key target region for all players in the global dystrophic epidermolysis bullosa treatment market. 

Asia Pacific is likely to be a highly lucrative market for dystrophic epidermolysis bullosa treatment from 2021 to 2030. The market in the region is projected to expand at a high CAGR during the forecast period.

Key Players

Key players in the global dystrophic epidermolysis bullosa treatment market include Krystal Biotech, Castle Creek Biosciences, Inc., Abeona Therapeutics, Inc., Amryt Pharma plc, Wings Therapeutics, Phoenix Tissue Repair, InMed Pharmaceuticals, Inc., RegeneRx, and Holostem Terapie Avanzate S.r.l.

Market Segmentation

By Treatment Type

• • Antibiotics
  • Corticosteroids
  • Opioid Analgesics
  • Anticonvulsant
  • Others

By Disease Type

• • Dominant Dystrophic Epidermolysis Bullosa (DDEB)
  • Recessive Dystrophic Epidermolysis Bullosa (RDEB)

By Distribution Channel

• • Hospital Pharmacies
  • Retail Pharmacies
  • Others

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Immediate Delivery Available | Buy this Premium Research Report@ https://www.visionresearchreports.com/report/cart/38187

You can place an order or ask any questions, please feel free to contact at sales@visionresearchreports.com | +1 9197 992 333